Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japan’s Emphasis On Generics Spurs Broad Production Expansion

This article was originally published in PharmAsia News

Executive Summary

Taking advantage of the government's push for lower-cost drugs, Japanese generics companies are more than doubling production. Next year, it is estimated national generic production will be as much as 2.3 times the size of last year's production capacity. Nichi-Iko Pharmaceutical alone plans to spend $66.5 million by the end of next year to expand capacity at just one plant, nearly doubling its oral medicines capability. Sawai Pharmaceutical, Towa Pharmaceutical and Nipro also plan expansions, and Taiyo Yakuhin expects its expanded facilities to be on-line in September, producing anti-cancer drugs. (Click here for more - a subscription may be required



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts